Identifying and Navigating Challenges Associated With Clinical Pathways in the Treatment of HCC

EP: 1.Evaluating Clinical Pathway Implementation in HCC Treatment

EP: 2.The Impact of Clinical Pathways on Healthcare Resource Allocation in HCC Management

Now Viewing

EP: 3.Identifying and Navigating Challenges Associated With Clinical Pathways in the Treatment of HCC

EP: 4.Clinical Pathways and Streamlined Decision-Making in HCC Management

EP: 5.Patient Engagement and Clinical Pathways in HCC

EP: 6.HIMALAYA Study and IMbrave150 Trial

EP: 7.Time-to-Response Correlation to HCC Treatment Effectiveness and Patient Prognosis

EP: 8.Navigating Adverse Events Associated With HCC Treatment

EP: 9.Managing Adverse Events to Sustain Continuity in HCC Treatment

EP: 10.Assessing Cost-Effective Treatment Options in HCC

EP: 11.The Decision-Making Process Behind Elective Gastroscopy (EGD) in the Treatment of HCC.

EP: 12.Maximizing Health Care Resource Utilization in HCC

EP: 13.Key Toxicity Profiles in the Treatment of HCC

EP: 14.Navigating HCC Treatment-Related Toxicities

EP: 15.Toxicity Profiles and Their Impact on the Quality of Life for Patients with HCC

EP: 16.Resource Allocation Strategies in HCC Treatment

EP: 17.Key Considerations in the Management of HCC

The panel discussion focused on the complexities surrounding the development and implementation of clinical pathways in the context of hepatocellular carcinoma (HCC) treatment. Mohamed Salem, MD, highlighted the importance of ensuring that the pathways developed are applicable to a diverse range of practices and centers, emphasizing the need for a more generalized approach. Challenges regarding the integration of cutting-edge research into established pathways were discussed, with Ghassan Abou-Alfa, MD, MBA, emphasizing the importance of basing updates on relevant data while maintaining an open, transparent, and democratic process.

The speakers acknowledged the potential conflicts of interest that could arise when experts involved in research attempt to influence the content of clinical pathways. Dr Abou-Alfa advocated for transparency and an open discussion to ensure that the decision-making process remains driven by objective data rather than individual preferences. The critical role of clinical trials and expert insights was emphasized, highlighting the need to integrate a shared decision-making framework to benefit patients effectively.

Additionally, the panel addressed the challenges associated with incorporating non–FDA approved treatments into clinical pathways, emphasizing the importance of balancing the need for timely updates with the requirement for vetted and approved treatments. Dr Salem’s insight underscored the necessity of navigating these challenges and finding a balance between prompt integration and regulatory approval.

Overall, the discussion shed light on the multifaceted nature of developing clinical pathways and highlighted the significance of aligning them with the latest research data and guidelines. The emphasis on transparency, data-driven decision-making and the collective expertise of the medical community emerged as critical themes throughout the conversation, ultimately underscoring the goal of optimizing patient outcomes and ensuring the highest standard of care for individuals with HCC.

Video synopsis is AI-generated and reviewed by AJMC editorial staff.